Dasatinib is a potent and targeted cancer drug belonging to a class of medications known as tyrosine kinase inhibitors (TKIs). It was initially developed to treat chronic myeloid leukemia (CML) and later found application in the management of other malignancies, notably Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and certain types of solid tumors. This article aims to provide an in-depth exploration of Dasatinib's mechanisms of action, its uses in various cancers ... Read more
